Aimovig Injection
Product Images NDC 55513-841

Product Visual Gallery

This gallery contains 66 technical images submitted to the FDA as part of the official labeling for Aimovig (NDC 55513-841). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Change From Baseline In Monthly Migraine Days In Study 1a (Aimovig 01)

This appears to be a chart or table displaying changes from baseline for a clinical trial involving a placebo and two different doses of a medication called Aimovig (70 mg and 140 mg). The data is organized by month, with columns for baseline and each month up to month 6. There are also two rows labeled "g" and "H" which may be related to the study protocol.*

FDA Label Image

Figure 2: Distribution Of Change From Baseline In Mean Monthly Migraine Days Over Months 4 To 6 By Treatment Group In Study 1 (Aimovig 02)

This is a chart providing the percentage of patients as per the number of days with migraine per month. The chart contains data of two groups, one given a placebo (N=289) and the other given AIMOVIG 70mg QM (N=296). The chart indicates that patients taking AIMOVIG had fewer migraine days per month compared to the placebo group. However, it does not provide any further details or context.*

FDA Label Image

Figure 3: Change From Baseline In Monthly Migraine Days In Study 2a (Aimovig 03)

This is a tabular representation of the change in monthly migraine days from the baseline to months 1, 2, and 3. The first row represents the placebo group, and the second row represents the group receiving AIMOVIG 70 mg QM. However, there is not enough information provided to give details beyond this.*

FDA Label Image

Figure 4: Distribution Of Change From Baseline In Monthly Migraine Days At Month 3 By Treatment Group In Study 2 (Aimovig 04)

FDA Label Image

Figure 5: Change From Baseline In Monthly Migraine Days In Study 3a (Aimovig 05)

The text appears to be a chart showing the change in monthly migraine days after using a placebo, AIMOVIG 70 mg QM, and AIMOVIG 140 mg QM over the course of 3 months. It is not possible to decipher the exact meaning of the numbers without more context.*

FDA Label Image

Figure 6: Distribution Of Change From Baseline In Monthly Migraine Days At Month 3 By Treatment Group In Study 3 (Aimovig 06)

This is a chart that shows the percentage of patients who experienced a reduction in the number of migraine days per month and the percentage of patients who experienced no change or an increase in the number of migraine days per month when taking either placebo, Aimovig 70 mg OM, or Aimovig 140 mg QM. The chart also shows the number of patients who were included in each group.*

FDA Label Image

Aimovig 07

This is a guide to parts for a medical device or medicine administration. It includes instructions on what each part is for before and after use, such as the purple start button, expiration dates, the yellow window, different guards for safety and needles, and when to remove the white cap.*

FDA Label Image

Guide To Parts (Aimovig 08)

FDA Label Image

Read This Before You Inject. (Aimovig 09)

FDA Label Image

Pinch Method (Aimovig 10)

This is a list of body parts consisting of the upper arm, stomach area or abdomen, and the thigh.*

FDA Label Image

G Hold The Stretch Or Pinch. With The White Cap Off, Place The Autoinjector On Your Skin At 90 Degrees. (Aimovig 11)

FDA Label Image

H Firmly Push The Autoinjector Down Onto Skin Until The Autoinjector Stops Moving. (Aimovig 12)

FDA Label Image

I When You Are Ready To Inject, Press The Purple Start Button. You Will Hear A Click. (Aimovig 13)

FDA Label Image

J Keep Pushing Down On Your Skin. Your Injection Could Take About 15 Seconds. When The Injection Is Complete, You May Hear Or Feel A Click And The Window Will Turn Yellow. (Aimovig 14)

FDA Label Image

K Discard The Used Autoinjector And The White Cap. (Aimovig 15)

The Pinch method is a hand gesture often used to assess dehydration in humans. It involves pinching the skin on the back of the hand and observing how quickly it returns to its normal position. If it takes longer than normal, it may be a sign of dehydration.*

FDA Label Image

Aimovig 16

FDA Label Image

This Product Contains Dry Natural Rubber (Aimovig 17)

FDA Label Image

Do Not Reuse (Aimovig 18)

FDA Label Image

Caution,consult Accompanying Documents (Aimovig 19)

Not available.*

FDA Label Image

D Prepare And Clean Your Injection Site. (Aimovig 20)

FDA Label Image

E Pull Gray Needle Cap Straight Out And Away From Your Body, Only When You Are Ready To Inject. Do Not Leave The Gray Needle Cap Off For More Than 5 Minutes. This Can Dry Out The Medicine. (Aimovig 21)

FDA Label Image

F Pinch Your Injection Site To Create A Firm Surface. (Aimovig 22)

FDA Label Image

G Hold The Pinch. With The Gray Needle Cap Off, Insert The Syringe Into Your Skin At 45 To 90 Degrees. (Aimovig 23)

FDA Label Image

H Place Your Finger On The Plunger Rod. Using Slow And Constant Pressure, Push The Plunger Rod All The Way Down Until The Prefilled Syringe Stops Moving. (Aimovig 24)

FDA Label Image

I When Done, Release Your Thumb, And Gently Lift The Syringe Off Of Your Skin. (Aimovig 25)

FDA Label Image

J Discard The Used Syringe And The Gray Needle Cap. (Aimovig 26)

FDA Label Image

This Product Contains Dry Natural Rubber (Aimovig 27)

This text appears to be a guide to the different parts of a device or product. It includes descriptions of buttons, windows, expiration dates, safety guards, and caps. The text does not provide enough context to determine what specific product or device this guide applies to.*

FDA Label Image

Principal Display Panel1 X 70 mg/ml Prefilled Autoinjectorndc 55513-841-01rx Onlyaimovig™(erenumab-aooe) Injection70 mg/ml70 mg/mlprefilled Autoinjector For Subcutaneous Use Only Store At 2°c To 8°c (36°f To 46°f) In Original Carton To Protect From Light. Do Not Freeze. Do Not Shake. Discard Any Unused Portion. Keep Out Of The Sight And Reach Of Children. For More Information, Go To Aimovig.com Orcall 1-800-77-amgen (1-800-772-6436). Caution, Consultaccompanying Documents Do Not Reuse This Product Containsdry Natural Rubber.no U.s. Standard Of Potency (Aimovig 28)

FDA Label Image

Principal Display Panel2 X 70 mg/ml Prefilled Autoinjectorsndc 55513-841-02rx Onlyaimovig™(erenumab-aooe) Injection70 mg/ml70 mg/ml140 mg/2 mL70 mg/mlprefilled Autoinjectors For Subcutaneous Use Only Store At 2°c To 8°c (36°f To 46°f) In Original Carton To Protect From Light. Do Not Freeze. Do Not Shake. Discard Any Unused Portion. Keep Out Of The Sight And Reach Of Children. For More Information, Go To Aimovig.com Orcall 1-800-77-amgen (1-800-772-6436). Caution, Consultaccompanying Documents Do Not Reuse This Product Containsdry Natural Rubber.no U.s. Standard Of Potency (Aimovig 29)

FDA Label Image

Aimovig 30

This appears to be a list of body parts with their respective names: upper arm, stomach area (abdomen), and thigh. It could be useful for identifying specific areas of the body or for medical documentation.*

FDA Label Image

Aimovig 31

FDA Label Image

Aimovig 32

FDA Label Image

Aimovig 33

FDA Label Image

Aimovig 34

FDA Label Image

Aimovig 35

The Pinch method is a technique used to estimate body fat percentage by measuring the thickness of skin folds in specific areas of the body, such as the triceps, abdomen, and thighs. By applying pressure to the skin fold, the thickness can be measured and used in a formula to estimate body fat percentage. This method is commonly used in fitness and health assessments to track progress and make adjustments to nutrition and exercise programs.*

FDA Label Image

Aimovig 36

FDA Label Image

Aimovig 37

FDA Label Image

Aimovig 38

FDA Label Image

Aimovig 39

FDA Label Image

Aimovig 40

FDA Label Image

Aimovig 41

FDA Label Image

Aimovig 42

FDA Label Image

Aimovig 43

FDA Label Image

Aimovig 44

FDA Label Image

Aimovig 45

FDA Label Image

Aimovig 46

FDA Label Image

Aimovig 47

This appears to be a guide to the different parts of a medical syringe, including the plunger rod, finger flange, label, expiration date, and needle. It also mentions the importance of replacing used parts and keeping a needle cap on when not in use.*

FDA Label Image

Aimovig 48

FDA Label Image

Aimovig 49

FDA Label Image

Aimovig 50

This appears to be a description of a syringe. It includes components such as the barrel, plunger, finger flange, expiration date rod, and a gray medicine needle cap. The syringe also seems to include a label and a possible needle inside the cap.*

FDA Label Image

Aimovig 51

FDA Label Image

Aimovig 52

The text describes three body parts: the upper arm, the stomach area (also known as the abdomen), and the thigh.*

FDA Label Image

Aimovig 53

FDA Label Image

Aimovig 54

FDA Label Image

Aimovig 55

FDA Label Image

Aimovig 56

FDA Label Image

Aimovig 57

FDA Label Image

Aimovig 58

FDA Label Image

Aimovig 59

FDA Label Image

Aimovig 60

FDA Label Image

Aimovig 61

FDA Label Image

Aimovig 62

FDA Label Image

Aimovig 63

FDA Label Image

Aimovig 64

This is a cautionary description about a medical product named "Aimovig" with the active ingredient "erenumab-aooe" in the form of autoinjector for subcutaneous use only. The medical product is to be stored in a refrigerated place between 2°C to 8°C, and the user is advised not to reuse the autoinjector. The product is not meant for children, and the user needs to discard any unused portion. The natural rubber is used in its making, and for more information on this product, the user is directed to visit the website aimovig.com or call 1-800-77-AMGEN (1-800-772-6436).*

FDA Label Image

Aimovig 65

This is a description of a medication called Aimovig. It comes in a prefilled autoinjector with a dose of 140 mg/mL for subcutaneous use only. The medication should be refrigerated at 2°C to 8°C and should not be frozen or shaken. The unused portion should be discarded. The label warns against reusing it and advises consulting accompanying documents. The product contains dry natural rubber. For more information, visit Aimovig.com or call 1-800-77-AMGEN.*

FDA Label Image

Aimovig 66

AIMOVIG is a medication used for subcutaneous injection to help prevent episodic or chronic migraines. The medication comes in a pre-filled syringe that contains 140 mg/mL of erenumab-aooe and should be stored refrigerated between 2°C to 8°C. Before using, the medicine should be allowed to sit at room temperature. The medication is protected from sunlight by keeping the cap on while allowing it to sit. Children should be kept away, and the packaging insert should be referred to for dosage and administration instructions. The text contains additional unrelated content that may be gibberish; however, this information is not available in English.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.